Baricitinib

BNF:
10.1.3
Status:
Red
Decision Date:
September 2017
 

Comments

RED:

  • NICE TA466: for moderate to severe rheumatoid arthritis. Selective JAK1/JAK2 inhibitor, JAK3-sparing, treatment of moderate-to-severe active rheumatoid arthritis.  (Decision date - September 2017)
  •  NICE TA681: for the treatment of moderate to severe atopic dermatitis.  (Decision date - April 2021)
  • for use in monogenic interferonopathies (adults and children 2 years and over). NHSE commissioned.  (Decision date - August 2021)

Red Drug Classifications

  • 1: Requiring specialist assessment to enable patient selection, initiation and ongoing treating
  • 2: Requiring long term on-going monitoring of efficacy by a specialist and not suitable for shared care

search again

Derby and Derbyshire ICB

Derby and Derbyshire ICB

Please click the button to navigate to our app

Redirect to app